tetano
Editor, Senior Moderator
Cell
. 2021 Oct 16;S0092-8674(21)01221-6.
doi: 10.1016/j.cell.2021.10.011. Online ahead of print.
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
Rebecca P Payne[SUP] 1 [/SUP], Stephanie Longet[SUP] 2 [/SUP], James A Austin[SUP] 3 [/SUP], Donal T Skelly[SUP] 4 [/SUP], Wanwisa Dejnirattisai[SUP] 2 [/SUP], Sandra Adele[SUP] 5 [/SUP], Naomi Meardon[SUP] 6 [/SUP], Sian Faustini[SUP] 7 [/SUP], Saly Al-Taei[SUP] 7 [/SUP], Shona C Moore[SUP] 3 [/SUP], Tom Tipton[SUP] 2 [/SUP], Luisa M Hering[SUP] 3 [/SUP], Adrienn Angyal[SUP] 8 [/SUP], Rebecca Brown[SUP] 8 [/SUP], Alexander R Nicols[SUP] 9 [/SUP], Natalie Gillson[SUP] 10 [/SUP], Susan L Dobson[SUP] 3 [/SUP], Ali Amini[SUP] 11 [/SUP], Piyada Supasa[SUP] 2 [/SUP], Andrew Cross[SUP] 12 [/SUP], Alice Bridges-Webb[SUP] 13 [/SUP], Laura Silva Reyes[SUP] 13 [/SUP], Aline Linder[SUP] 13 [/SUP], Gurjinder Sandhar[SUP] 8 [/SUP], Jonathan A Kilby[SUP] 8 [/SUP], Jessica K Tyerman[SUP] 9 [/SUP], Thomas Altmann[SUP] 14 [/SUP], Hailey Hornsby[SUP] 8 [/SUP], Rachel Whitham[SUP] 6 [/SUP], Eloise Phillips[SUP] 5 [/SUP], Tom Malone[SUP] 5 [/SUP], Alexander Hargreaves[SUP] 2 [/SUP], Adrian Shields[SUP] 15 [/SUP], Ayoub Saei[SUP] 10 [/SUP], Sarah Foulkes[SUP] 10 [/SUP], Lizzie Stafford[SUP] 16 [/SUP], Sile Johnson[SUP] 17 [/SUP], Daniel G Wootton[SUP] 18 [/SUP], Christopher P Conlon[SUP] 19 [/SUP], Katie Jeffery[SUP] 20 [/SUP], Philippa C Matthews[SUP] 21 [/SUP], John Frater[SUP] 21 [/SUP], Alexandra S Deeks[SUP] 21 [/SUP], Andrew J Pollard[SUP] 22 [/SUP], Anthony Brown[SUP] 5 [/SUP], Sarah L Rowland-Jones[SUP] 23 [/SUP], Juthathip Mongkolsapaya[SUP] 24 [/SUP], Eleanor Barnes[SUP] 25 [/SUP], Susan Hopkins[SUP] 26 [/SUP], Victoria Hall[SUP] 27 [/SUP], Christina Dold[SUP] 22 [/SUP], Christopher J A Duncan[SUP] 28 [/SUP], Alex Richter[SUP] 15 [/SUP], Miles Carroll[SUP] 2 [/SUP], Gavin Screaton[SUP] 2 [/SUP], Thushan I de Silva[SUP] 23 [/SUP], Lance Turtle[SUP] 29 [/SUP], Paul Klenerman[SUP] 30 [/SUP], Susanna Dunachie[SUP] 31 [/SUP], PITCH Consortium
Collaborators, Affiliations
Abstract
Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the United Kingdom to accelerate population coverage with a single dose. At this time, trial data were lacking, and we addressed this in a study of United Kingdom healthcare workers. The first vaccine dose induced protection from infection from the circulating alpha (B.1.1.7) variant over several weeks. In a substudy of 589 individuals, we show that this single dose induces severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody (NAb) responses and a sustained B and T cell response to the spike protein. NAb levels were higher after the extended dosing interval (6-14 weeks) compared with the conventional 3- to 4-week regimen, accompanied by enrichment of CD4[SUP]+[/SUP] T cells expressing interleukin-2 (IL-2). Prior SARS-CoV-2 infection amplified and accelerated the response. These data on dynamic cellular and humoral responses indicate that extension of the dosing interval is an effective immunogenic protocol.
Keywords: B cell; BNT162b2; COVID-19; SARS-CoV-2; T cell; antibody; dosing interval; neutralization; vaccine; variants of concern.
. 2021 Oct 16;S0092-8674(21)01221-6.
doi: 10.1016/j.cell.2021.10.011. Online ahead of print.
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
Rebecca P Payne[SUP] 1 [/SUP], Stephanie Longet[SUP] 2 [/SUP], James A Austin[SUP] 3 [/SUP], Donal T Skelly[SUP] 4 [/SUP], Wanwisa Dejnirattisai[SUP] 2 [/SUP], Sandra Adele[SUP] 5 [/SUP], Naomi Meardon[SUP] 6 [/SUP], Sian Faustini[SUP] 7 [/SUP], Saly Al-Taei[SUP] 7 [/SUP], Shona C Moore[SUP] 3 [/SUP], Tom Tipton[SUP] 2 [/SUP], Luisa M Hering[SUP] 3 [/SUP], Adrienn Angyal[SUP] 8 [/SUP], Rebecca Brown[SUP] 8 [/SUP], Alexander R Nicols[SUP] 9 [/SUP], Natalie Gillson[SUP] 10 [/SUP], Susan L Dobson[SUP] 3 [/SUP], Ali Amini[SUP] 11 [/SUP], Piyada Supasa[SUP] 2 [/SUP], Andrew Cross[SUP] 12 [/SUP], Alice Bridges-Webb[SUP] 13 [/SUP], Laura Silva Reyes[SUP] 13 [/SUP], Aline Linder[SUP] 13 [/SUP], Gurjinder Sandhar[SUP] 8 [/SUP], Jonathan A Kilby[SUP] 8 [/SUP], Jessica K Tyerman[SUP] 9 [/SUP], Thomas Altmann[SUP] 14 [/SUP], Hailey Hornsby[SUP] 8 [/SUP], Rachel Whitham[SUP] 6 [/SUP], Eloise Phillips[SUP] 5 [/SUP], Tom Malone[SUP] 5 [/SUP], Alexander Hargreaves[SUP] 2 [/SUP], Adrian Shields[SUP] 15 [/SUP], Ayoub Saei[SUP] 10 [/SUP], Sarah Foulkes[SUP] 10 [/SUP], Lizzie Stafford[SUP] 16 [/SUP], Sile Johnson[SUP] 17 [/SUP], Daniel G Wootton[SUP] 18 [/SUP], Christopher P Conlon[SUP] 19 [/SUP], Katie Jeffery[SUP] 20 [/SUP], Philippa C Matthews[SUP] 21 [/SUP], John Frater[SUP] 21 [/SUP], Alexandra S Deeks[SUP] 21 [/SUP], Andrew J Pollard[SUP] 22 [/SUP], Anthony Brown[SUP] 5 [/SUP], Sarah L Rowland-Jones[SUP] 23 [/SUP], Juthathip Mongkolsapaya[SUP] 24 [/SUP], Eleanor Barnes[SUP] 25 [/SUP], Susan Hopkins[SUP] 26 [/SUP], Victoria Hall[SUP] 27 [/SUP], Christina Dold[SUP] 22 [/SUP], Christopher J A Duncan[SUP] 28 [/SUP], Alex Richter[SUP] 15 [/SUP], Miles Carroll[SUP] 2 [/SUP], Gavin Screaton[SUP] 2 [/SUP], Thushan I de Silva[SUP] 23 [/SUP], Lance Turtle[SUP] 29 [/SUP], Paul Klenerman[SUP] 30 [/SUP], Susanna Dunachie[SUP] 31 [/SUP], PITCH Consortium
Collaborators, Affiliations
- PMID: 34735795
- DOI: 10.1016/j.cell.2021.10.011
Abstract
Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the United Kingdom to accelerate population coverage with a single dose. At this time, trial data were lacking, and we addressed this in a study of United Kingdom healthcare workers. The first vaccine dose induced protection from infection from the circulating alpha (B.1.1.7) variant over several weeks. In a substudy of 589 individuals, we show that this single dose induces severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody (NAb) responses and a sustained B and T cell response to the spike protein. NAb levels were higher after the extended dosing interval (6-14 weeks) compared with the conventional 3- to 4-week regimen, accompanied by enrichment of CD4[SUP]+[/SUP] T cells expressing interleukin-2 (IL-2). Prior SARS-CoV-2 infection amplified and accelerated the response. These data on dynamic cellular and humoral responses indicate that extension of the dosing interval is an effective immunogenic protocol.
Keywords: B cell; BNT162b2; COVID-19; SARS-CoV-2; T cell; antibody; dosing interval; neutralization; vaccine; variants of concern.